Nexgel, Inc.NXGL

NEXGEL, Inc. (Langhorne, Pennsylvania) filed its latest 10-Q on 23 May 2026 and the headline number is plain: revenue for the quarter ended 31 March 2026 was $2.6 million, up from $2.4 million in the same three months of 2025, yet the company still lost $927,000 and reported negative operating income of $958,000. Diluted EPS clocked in at minus $0.11 on 8.2 million shares, while cash used in operations totalled $504,000. On the bright side, the company’s cash and equivalents sat at $938,000 at 30 September 2025, giving it a slender liquidity buffer while it tries to monetise a hydrogel platform that can be made with or without active ingredients.

The company describes itself as an FDA-registered and ISO-certified facility whose “Synapse” patch uses only 55% water and bills itself as “our most adherent patch product,” positioning the technology for both healthcare and cosmetics. The investor site touts NEXGEL as “a leading provider of ultra-gentle, high-water-content hydrogels,” a phrase that trips lightly off the tongue but has yet to show up in the cash-flow statement. The company’s official site shows product imagery of a skin-friendly patch with the tagline “Your Skin Friendly Patch Company,” language that suggests a consumer brand in the making rather than the micro-cap contract manufacturer that the filings actually reveal.

According to the 10-Q, total assets stood at $11.6 million against liabilities of $7.1 million, leaving shareholders’ equity at $4.0 million. Inventory rose by $152,000 to $2.3 million in the quarter, an increase the company does not explain in the filing. Capital expenditure for the year to 31 December 2025 was a modest $68,000, and research and development expense for the same period was reported at just $1,000, figures that suggest the company is conserving cash while it waits for a product cycle to bear fruit. The company told investors on 15 May 2026 that it would report first-quarter results on 15 May 2026, a circularity that underlines how thin the disclosure trail remains.

NEXGEL’s most recent 8-K, filed on 9 July 2026, discloses the appointment of Dave Hazard as Vice President of Sales for BIONX Surgical on 2 July 2026, a move that looks like an attempt to beef up commercial execution in a surgical segment while the broader business remains subscale. The company’s 8-K dated 17 June 2026 and its ownership XML filings from 9, 15 and 23 June 2026 show routine updates to director and officer shareholdings, but none of the documents quantify how many patches NEXGEL actually shipped or how many customers paid for them. The absence of segment-level revenue, customer concentration metrics, or backlog disclosure means the source requires readers to take the “leading provider” claim on trust rather than on the evidence supplied.

If you want to see the product in question, the company’s official site hosts an image of the Synapse patch under the heading “NexGel SkinFriendlyPatchCo,” an image that proves the product exists but does not prove it is selling at scale. The company’s investor relations pages repeat the same messaging, adding only that the platform can be manufactured “with or without active ingredients,” a flexibility that sounds impressive until you realise the filings do not show a single profitable quarter. In short, NEXGEL’s platform is real, its certifications are real, and its latest executive hire is real; what remains unproven is whether any of it adds up to a sustainable business before the $938,000 in cash on hand runs low.